Dmitry Kravchenko Email & Phone Number

Thank you for reviewing my professional background.● Board certified medical oncologist M.D., Ph.D. with 14+ years of extensive clinical and research experience in adult solid tumors;● Industry experience: advisor for 3 pre-clinical trials, pipeline development;● Clinical trial experience: co-investigator in phase II-III international clinical trials.● Advanced experience in cancer immunotherapy (immune checkpoint inhibitors, mAbs, ADCs, CAR-T), solid expertise in cancer biology, immunology (including CAR-T, TCR, BiTE), cell therapy, and genetics.● Passionate about clinical development (immuno-oncology, CAR-T-based approaches for solid tumors, autoimmune and infectious diseases), translating molecular discoveries into clinical practice, developing talent, and advancing international global programs to treat and cure cancer. Considering moving from academia to industry/biotech/CRO.Clinical experience:2010 - now: various public and private hospitals, Moscow, Russia.• Treatment and management of adult cancer patients, chemo-, targeted, immunotherapy of solid tumors (NSCLC, breast, GI, GU, melanoma), participating in weekly multidisciplinary tumor boards;• Interpretation and analysis of NGS (next-generation sequencing) to individually tailor cancer therapies.Industry experience:04-07.2021: research enablement platform “Guidepoint”, New York, USA (remote).• Advisor for design, feasibility, and conduct of 3 pre-clinical trials with pipeline development.• Provided scientific and clinical insights to optimize pre-clinical programs that decreased pre-clinical drug development timeline by 5%.Clinical trial experience: 2017 – now:● Phase II/III and EAP of Kymriah (CAR-T), Yescarta (CAR-T), alpelisib, nintedanib, olaparib, ribociclib, kadcyla, enhertu, pembrolizumab, nivolumab, ipilimumab in various indications (adult metastatic/advanced tumors), to accelerate access and delivery of life saving cancer treatments.● WO42178/ENGOT-GYN2/GOG-3051, a Phase II, multicenter, Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors: ipatasertib and paclitaxel, cobimetinib, trastuzumab emtansine, atezolizumab and bevacizumab, giredestrant and abemaciclib, inavolisib and palbociclib, letrozole, olaparib.Sub-investigator functionality:● Pre-selection of study participants, work with referrals● Consent and enrollment● Response assessment (RECIST)● Safety assessment and adverse events documentation (CTCAE).